Welcome, Guest Login | Register

Tuesday, Aug 28, 2012

Home | Markets & Investing | Companies & Industry

Advanced Search RSS Content Guide

Follow us on

| Banking & Finance | Economy & Policy | Opinion | Life & Leisure | Mgmt & Mktg | Technology | BS Products

Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & A nalysis | Opinion | Corporate Results Home > Companies & Industry

Live Markets | Commodities

Text or company name

Keyword

Go

Email this

Facebook

Twitter

Share

Print this

API market loses out to formulations

Change in trend attributed to the high-margin business of finished products
Sushm i Dey / New Delhi Aug 27, 2012, 00:47 IST
Ads by Google

Lupin Pharma Europe : Leading European Generic Developer View product list & make enquiries
www.genericlicensing.com/lupin Once a favoured destination for sourcing low-cost, good quality ingredients for pharmaceutical formulations, India has now turned to manufacturing of finished products in a big way. Wanting to move up the value chain, leading drug makers like Ranbaxy, Sun Pharma, Aurobindo Pharma, Lupin and others have made this shift in the last few years. API is the active chemical or ingredient used in the manufacturing of a dosage form of a drug. Currently, API accounts for around 10 per cent of Indias Rs 65,000-crore pharmaceutical market. The rest comprises formulations. In 2007, when the total Indian pharmaceutical market was estimated to be Rs 35,000 crore, APIs accounted for almost 15-20 per cent. In the last few years, China has emerged as a major API producer with its landed price in India being much less than its production cost here. Indian drug makers now want to move up the value chain, analysts say. With massive economies of scale their forte, China provides APIs at a cost 1520 per cent lower. However, this is also an opportunity for the Indian companies who have good chemistry skills required for the development of formulations. Those can now source cheaper raw material from China and themselves move up the value chain with finished products, said Praful Bohra, senior research analyst, Nirmal Bang. Many of Indias leading drug companies manufacturing both formulations and APIs have drastically shifted focus from API over the past few years. According to a Ranbaxy official, at present the API mix in its total revenues is as low as four to five per cent. Similarly, Lupin, which had around 40 per cent of its total sales coming from APIs in 2004-2005, now gets only 10 to 11 per cent from the segment. Sun Pharmas API share has also fallen to seven per cent of its total revenue from 10 per cent four to five years ago. Long Term BlueChip Shares
Exclusive List of Indian BlueC hip Shares. Get it Free. Act Now!

Equitym aste r.com /Blue C hip-Shar

However, these companies maintain the production of APIs in absolute term has Submit Your Resume 2-10 years Exp. Salary 3-15 not dropped, but has decreased as a percentage of their total mix as the Lakhs. To Apply, Register on formulation business grows faster.
Shine.com Now

Another major reason for the shift in focus is formulations is a high-margin business compared to APIs, which is a mere commodity business. APIs is a simple commodity business with very low margins. It is mainly for starters who can develop scalable capacities. We have skills and have an eye on the bottom line. We also produce APIs that are mostly new ingredients and useful in our internal business. Our external sales is coming from value-added formulations, says Lupin CFO Ramesh Swaminathan. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture lowcost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs. Outside the US, India has the largest number of manufacturing facilities approved by the US Food and Drugs Administration.

Shine .com /Pharm a_Jobs

Also Read
Related Stories News Now

- Flip-flop in the pharma sector - Analysts' corner - Pharmaceuticals: June quarter shows the way - 'Ranbaxy drug pull-out in US shows progress in relations with US FDA' - Sensex ends flat, doubts grow

www.business-standard.com/india/news/api-market-loses-out-to-formulations/484518/

1/3

Recently, Sandoz, the generic drug division of the Swiss drug maker, Novartis, closed its API development unit near Mumbai. While Novartis India ViceChairman & Managing Director Ranjit Shahani said the decision was part of a project portfolio optimisation within Sandoz Global Development, analysts suggest it could be due to cost-benefit analysis of the company.

- Sensex ends flat, doubts grow whether gains can sustain - Drug makers to sustain premium valuations: HSBC

This could be because the company aims to focus on drug development and R&D in formulations. In that case, it makes sense for the company to even get API from others. This will save them a lot of energy and resources. Plus, the focus will remain on formulations, an analyst said.

New Ipad Application :Business Standard's all new IPad App Click here to download for free

Other Stories
Pre-market: Rangebound trade likely Apple seeks quick bans on eight Samsung phones GAIL to buy 12 LNG cargoes from GDF Suez in 2013-14 Gold price highest since April on stimulus hopes India, China press each other for market access

Tags : PHARMA FOCUS SHIFTS | Ranbaxy | Sun Pharma | Aurobindo Pharma | Lupin | Praful Bohra |

Ramesh Swaminathan | Novartis India | Ranjit Shahani |

Table for Two Now available at Special price Rs.280/- Only Buy Now Advertisements

Read Business news in

- Start Drive with Farhan Akthar. Click here to know more - Free bluetooth handset with every purchase of Tab 2 (P310) - Explore the exciting features of the LG Cinema 3D Smart TV. - Leadership is number one Everything else is less. Click here - Free HP 8 GB Pen Drive Worth Rs. 1500/- with 12A Toner. Click here - The Biggest gathering of job above 15 Lakh CTC. Click here - Fly Daily to Washington, DC from INR 63047 from 12th September 2012 - Imagine a place where children can... Click here to know more - Choose a fixed period of up to 10 years & enjoy 10.75% p.a. - Efficient airport infrastructure helps people save time whenever they fly. - Presenting the 2012 North American Car of the Year. Click here - Try the smarter way to save regulary! Know More - Get Smarter with Teamcenter 9. Smarter decisions, better products. - Experience The Smartest 3D TV Minimized Frame, Minimized 3D - For Improved Productivity & Better Storage Efficiency. Click here - Now Buy a New Broadband online & Get Rs 500 Cashback. - Power Projects at Asia's Largest Solar Park. Click here - Trustworthy Innovative Solutions To Realize Potential. Click here

BS POLL
Should there be reservation in promotion? Read the story
Yes No

Ads by Google

Pharma Research

Pharma Business

India Stock Market

Pharma Sales

Share this Story

Print this del.icio.us orkut Email this digg
0

Add to favorites newsVine

Share 3

Twitter Reddit

Facebook

Discussion Board/User Comments (0)

Display Name Post your comment Email-Id

www.business-standard.com/india/news/api-market-loses-out-to-formulations/484518/

2/3

Latest Messages

Most Popular
Read E-Mailed Commented

GAIL to buy 12 LNG cargoes from GDF Suez in 2013/14

- Gold to continue record run - Markets remain subdued -

India, China meet to resolve trade matters, strengthen ties A regulation a day keeps business away: Parekh
More

Tax Shastra Now available at Special price Rs. 360/- Only Buy Now

Find us on Facebook

Business Standard
Like You like this.

19,479 people like Business Standard.

Rushiraj

Bhupen

G hanshy am

N ishith

S ury abhan

F acebook social plugin

Member Area Subscribe to BS Products

Write to the Editor BS print product BS Hindi

RSS BS e-paper BS Motoring

Archives Newsletter BS Books

Advanced Search Portfolio Tracker

Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion Life & Leisure | Management & Marketing | Tech World | General News About Us | Partner With Us | Code of Conduct | Careers | Advertise with us | Terms & Conditions | Disclaimer | Contact Us

www.business-standard.com/india/news/api-market-loses-out-to-formulations/484518/

3/3